RayKnowChina Research Map
Shortlist

Not yet recruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRI

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Fudan University Shanghai Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07419867, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 70 years; sex: women only

    Registered eligibility fields

  2. Histologically confirmed invasive breast cancer.

    Inclusion criterion 3

  3. Women of childbearing potential must have a negative serum pregnancy test. Such patients must use a medically acceptable method of contraception during study treatment and for at least 6 months after the last dose of the study drug(s).

    Inclusion criterion 16

    Major surgery within 4 weeks prior to randomization without full recovery, or an anticipated need for major surgery during study treatment.

    Exclusion criterion 5

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

    Inclusion criterion 2

  5. Hemoglobin (Hb)≥90 g/L;

    Inclusion criterion 7

    Absolute neutrophil count (ANC)≥1.5×10\^9/L;

    Inclusion criterion 8

    Platelet count (PLT)≥100×10\^9/L;

    Inclusion criterion 9

    Total bilirubin (TBIL)≤1.5×the upper limit of normal (ULN);

    Inclusion criterion 10

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5×ULN;

    Inclusion criterion 11

    Alkaline phosphatase (ALP)≤2.5×ULN;

    Inclusion criterion 12

    Serum creatinine (Cr)≤1.5×ULN;

    Inclusion criterion 13

    Prothrombin time (PT) and activated partial thromboplastin time (APTT)≤1.5×ULN, and international normalized ratio (INR)≤1.5×ULN (in patients not receiving anticoagulation).

    Inclusion criterion 14

  6. At least one measurable lesion according to RECIST 1.1.

    Inclusion criterion 5

  7. Any other malignancy within the past 5 years, except cured cervical carcinoma in situ and non-melanoma skin cancer.

    Exclusion criterion 1

    Known active liver disease, including but not limited to active hepatitis B (defined as HBsAg positive with HBV-DNA≥1000 IU/mL), hepatitis C (defined as HCV-Ab positive with HCV-RNA above the assay's lower limit of quantification), or autoimmune liver disease.

    Exclusion criterion 6

  8. Pregnant or breastfeeding.

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07419867, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Female patients aged 18 to 70 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Histologically confirmed invasive breast cancer.
  • Known ER, PR and HER2 status.
  • At least one measurable lesion according to RECIST 1.1.
  • Adequate organ function, meeting all of the following:
  • Hemoglobin (Hb)≥90 g/L;
  • Absolute neutrophil count (ANC)≥1.5×10\^9/L;
  • Platelet count (PLT)≥100×10\^9/L;
  • Total bilirubin (TBIL)≤1.5×the upper limit of normal (ULN);
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5×ULN;
  • Alkaline phosphatase (ALP)≤2.5×ULN;
  • Serum creatinine (Cr)≤1.5×ULN;
  • Prothrombin time (PT) and activated partial thromboplastin time (APTT)≤1.5×ULN, and international normalized ratio (INR)≤1.5×ULN (in patients not receiving anticoagulation).
  • Left ventricular ejection fraction (LVEF)≥55% at baseline as measured by echocardiography or multi-gated acquisition (MUGA) scan.
  • Women of childbearing potential must have a negative serum pregnancy test. Such patients must use a medically acceptable method of contraception during study treatment and for at least 6 months after the last dose of the study drug(s).
  • The subject voluntarily agrees to participate, signs the informed consent form, has good compliance, and is willing to adhere to follow-up.

Exclusion Criteria:

  • Any other malignancy within the past 5 years, except cured cervical carcinoma in situ and non-melanoma skin cancer.
  • Diabetics or those allergic to radionuclides who are not suitable for 18F-FDG PET/MR examination.
  • Serious cardiovascular or cerebrovascular disease within 6 months prior to randomization, including but not limited to congestive heart failure, unstable angina, severe arrhythmias uncontrolled by medication, severe conduction abnormalities or clinically significant valvular disease, uncontrolled severe hypertension, myocardial infarction, or cerebrovascular accident.
  • Any serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
  • Major surgery within 4 weeks prior to randomization without full recovery, or an anticipated need for major surgery during study treatment.
  • Known active liver disease, including but not limited to active hepatitis B (defined as HBsAg positive with HBV-DNA≥1000 IU/mL), hepatitis C (defined as HCV-Ab positive with HCV-RNA above the assay's lower limit of quantification), or autoimmune liver disease.
  • Severe and uncontrolled infection or known HIV infection.
  • Active systemic bacterial infection (requiring intravenous antibiotics at time of initiating study treatment) or fungal infection.
  • Pregnant or breastfeeding.
  • Known allergy to the study drug or any of its excipients, or a history of severe hypersensitivity reactions to other monoclonal antibodies.
  • Known abuse of psychotropic substances, alcoholism, or drug abuse.
  • Known, definite neurological or psychiatric disorders associated with poor compliance, including but not limited to epilepsy or dementia.
  • Any other serious physical or mental illness or laboratory abnormality that may increase the risk of study participation or interfere with study treatment and outcomes, or any other condition that, in the investigator's judgment, makes the patient unsuitable for this study.
  • Receiving radiotherapy (except for palliative reasons), chemotherapy and immunotherapy within 3 weeks before treatment, excluding bisphosphonates (can be used for bone metastasis).

Quoted from ClinicalTrials.gov, NCT07419867, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07419867, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07419867